Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ondansetron - ADial Pharmaceuticals

Next Previous
Drug Profile

Ondansetron - ADial Pharmaceuticals

Alternative Names: AD-04

Latest Information Update: 17 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Virginia
  • Developer ADial Pharmaceuticals; University of Virginia
  • Class Anti-inflammatories; Antiemetics; Antipsychotics; Carbazoles; Drug withdrawal therapies; Imidazoles; Irritable bowel syndrome therapies; Obesity therapies; Small molecules; Smoking cessation therapies
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Alcoholism
  • No development reported Obesity; Opioid-related disorders; Smoking withdrawal

Most Recent Events

  • 10 Apr 2024 Pharmacodynamics and adverse events data from a phase III trial in Alcoholism released by Adial Pharmaceuticals
  • 20 Feb 2024 ADial Pharmaceuticals has patent protection for AD 04 in USA
  • 14 Feb 2024 Adial Pharmaceuticals receives patent allowance for genetic diagnostic to identify patients with specific genotypes for genetically targeted treatment of alcohol use disorder (AUD) in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top